Cd16a binding agents and uses thereof

Abstract

Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application No. 62 / 614,607, filed Jan. 8, 2018, the entirety of which is incorporated herein by reference.TECHNICAL FIELD[0002]The present disclosure encompasses technologies for modulating immune activities, e.g., for treatment of various conditions, disorders or diseases. In some embodiments, the present disclosure relates to compounds and methods useful as enhancing activities of antibodies, e.g., monoclonal antibodies. In some embodiments, the disclosure also provides pharmaceutically acceptable compositions comprising provided compounds and methods of using said compositions in the treatment of various conditions, disorders or diseases, e.g., various cancers.BACKGROUND[0003]The search for new therapeutic agents has been greatly aided in recent years by the discovery and development of monoclonal antibody therapeutic agents. Several of such agents elicit their therapeutic effect thr...

AI Technical Summary

Benefits of technology

The patent text describes methods and compounds that can help trigger, enhance, or generate the recruitment of immune cells to target damaged or disease cells. This can improve the effectiveness and reduce the toxicity of therapies. The patent also describes a platform called MATEs™, which can enhance the activity of antibodies by linking them to small molecule ligands. This can provide better results in treating disease by enhancing the recruitment of immune cells. Overall, the patent provides useful tools for improving the immune response and developing new therapies.

Problems solved by technology

Without the intention to be limited by any theory, Applicant recognizes that such less effective interactions may lead to less effective recruitments of immune cells expressing CD16a (e.g., NK cells) and / or reduced therapeutic effects (e.g., in heterozygous or homozygous subjects expressing a low-affinity form).

Images